NoCanTher SIGNED
Nanomedicine upscaling for early clinical phases of multimodal cancer therapy
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0NoCanTher project word cloud
Explore the words cloud of the NoCanTher project. It provides you a very rough idea of what is the project "NoCanTher" about.
Project "NoCanTher" data sheet
The following table provides information about the project.
| Coordinator |
FUNDACION IMDEA NANOCIENCIA
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.nocanther-project.eu/ |
| Total cost | 7˙113˙778 € |
| EC max contribution | 7˙113˙778 € (100%) |
| Programme |
1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies) |
| Code Call | H2020-NMP-2015-two-stage |
| Funding Scheme | RIA |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-04-01 to 2021-03-31 |
Partnership
Take a look of project's partnership.
Map
Project objective
This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project.
The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer.
NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities:
• Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process. • Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD).
This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).
Deliverables
| Public Web Site and Project Presentation | Websites, patent fillings, videos etc. | 2020-02-25 11:29:43 |
Take a look to the deliverables list in detail: detailed list of NoCanTher deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2017 |
Paul Southern, Quentin A. Pankhurst Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models published pages: 671-686, ISSN: 0265-6736, DOI: 10.1080/02656736.2017.1365953 |
International Journal of Hyperthermia 34/6 | 2020-02-25 |
| 2017 |
Amanda K Silva, Alba Nicolas-Boluda, Laura Fouassier, Florence Gazeau Overcoming the tumor microenvironment: the role of nanohyperthermia published pages: 1213-1215, ISSN: 1743-5889, DOI: 10.2217/nnm-2017-0096 |
Nanomedicine 12/11 | 2020-02-25 |
| 2017 |
Sandra Hallasch, Sindy Frick, Maximilian Jung, Ingrid Hilger How gastrin-releasing peptide receptor (GRPR) and αvβ3 integrin expression reflect reorganization features of tumors after hyperthermia treatments published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-017-06100-7 |
Scientific Reports 7/1 | 2020-02-25 |
| 2017 |
Jelena Kolosnjaj-Tabi, Iris Marangon, Alba Nicolas-Boluda, Amanda K.A. Silva, Florence Gazeau Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix published pages: 123-137, ISSN: 1043-6618, DOI: 10.1016/j.phrs.2017.07.010 |
Pharmacological Research 126 | 2020-02-25 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOCANTHER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NOCANTHER" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.2.1.2.)
nTRACK (2017)
Multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration
Read MoreiNanoBIT (2017)
Integration of Nano- and Biotechnology for beta-cell and islet Transplantation
Read MoreIMPETUS (2018)
Pilot line for paper based electrochemical test strips dedicated to quantitative biosensing in liquids
Read More